MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - GSK PHARMA
SUN PHARMA vs GSK PHARMA - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
GSK PHARMA 
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Current Valuations
| SUN PHARMA | GSK PHARMA | SUN PHARMA/ GSK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 32.6 | 46.2 | 70.6% | View Chart |
| P/BV | x | 2.7 | 9.2 | 29.7% | View Chart |
| Dividend Yield | % | 0.5 | 1.7 | 26.9% |
Financials
 SUN PHARMA  GSK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-18 |
GSK PHARMA Mar-19 |
SUN PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 701 | 3,595 | 19.5% | |
| Low | Rs | 433 | 1,253 | 34.6% | |
| Sales per share (Unadj.) | Rs | 110.4 | 184.7 | 59.8% | |
| Earnings per share (Unadj.) | Rs | 11.0 | 26.3 | 41.8% | |
| Cash flow per share (Unadj.) | Rs | 17.2 | 29.2 | 59.1% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 20.00 | 10.0% | |
| Dividend yield (eoy) | % | 0.4 | 0.8 | 42.8% | |
| Book value per share (Unadj.) | Rs | 158.8 | 126.3 | 125.7% | |
| Shares outstanding (eoy) | m | 2,399.26 | 169.40 | 1,416.3% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.1 | 13.1 | 39.1% | |
| Avg P/E ratio | x | 51.6 | 92.2 | 56.0% | |
| P/CF ratio (eoy) | x | 32.9 | 83.1 | 39.6% | |
| Price / Book Value ratio | x | 3.6 | 19.2 | 18.6% | |
| Dividend payout | % | 18.2 | 76.1 | 24.0% | |
| Avg Mkt Cap | Rs m | 1,360,021 | 410,626 | 331.2% | |
| No. of employees | `000 | 17.8 | 5.0 | 358.6% | |
| Total wages/salary | Rs m | 53,671 | 5,372 | 999.1% | |
| Avg. sales/employee | Rs Th | 14,890.9 | 6,306.7 | 236.1% | |
| Avg. wages/employee | Rs Th | 3,017.1 | 1,083.1 | 278.6% | |
| Avg. net profit/employee | Rs Th | 1,480.6 | 898.0 | 164.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 264,895 | 31,281 | 846.8% | |
| Other income | Rs m | 8,388 | 1,023 | 819.8% | |
| Total revenues | Rs m | 273,282 | 32,304 | 846.0% | |
| Gross profit | Rs m | 56,081 | 6,009 | 933.3% | |
| Depreciation | Rs m | 14,998 | 486 | 3,086.1% | |
| Interest | Rs m | 5,176 | 6 | 86,261.7% | |
| Profit before tax | Rs m | 44,295 | 6,540 | 677.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -9,505 | 287 | -3,311.8% | |
| Tax | Rs m | 8,452 | 2,373 | 356.2% | |
| Profit after tax | Rs m | 26,338 | 4,454 | 591.3% | |
| Gross profit margin | % | 21.2 | 19.2 | 110.2% | |
| Effective tax rate | % | 19.1 | 36.3 | 52.6% | |
| Net profit margin | % | 9.9 | 14.2 | 69.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,359 | 20,061 | 1,577.0% | |
| Current liabilities | Rs m | 198,643 | 14,543 | 1,365.9% | |
| Net working cap to sales | % | 44.4 | 17.6 | 251.9% | |
| Current ratio | x | 1.6 | 1.4 | 115.5% | |
| Inventory Days | Days | 95 | 57 | 167.0% | |
| Debtors Days | Days | 108 | 14 | 765.9% | |
| Net fixed assets | Rs m | 213,178 | 14,343 | 1,486.3% | |
| Share capital | Rs m | 2,399 | 1,694 | 141.6% | |
| "Free" reserves | Rs m | 378,606 | 19,704 | 1,921.4% | |
| Net worth | Rs m | 381,006 | 21,398 | 1,780.5% | |
| Long term debt | Rs m | 17,721 | 2 | 886,045.0% | |
| Total assets | Rs m | 643,028 | 39,113 | 1,644.0% | |
| Interest coverage | x | 9.6 | 1,091.0 | 0.9% | |
| Debt to equity ratio | x | 0 | 0 | 49,762.6% | |
| Sales to assets ratio | x | 0.4 | 0.8 | 51.5% | |
| Return on assets | % | 4.9 | 11.4 | 43.0% | |
| Return on equity | % | 6.9 | 20.8 | 33.2% | |
| Return on capital | % | 10.0 | 31.9 | 31.4% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 40,816 | 534 | 7,643.5% | |
| Fx outflow | Rs m | 30,143 | 7,091 | 425.1% | |
| Net fx | Rs m | 10,673 | -6,557 | -162.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 39,072 | 3,994 | 978.3% | |
| From Investments | Rs m | -33,708 | -1,433 | 2,351.6% | |
| From Financial Activity | Rs m | -15,393 | -3,584 | 429.5% | |
| Net Cashflow | Rs m | -7,359 | -1,023 | 719.2% | |
Share Holding
| Indian Promoters | % | 63.7 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 50.7 | - | |
| Indian inst/Mut Fund | % | 5.1 | 10.2 | 50.3% | |
| FIIs | % | 23.0 | 23.8 | 96.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.3 | 15.4 | 53.9% | |
| Shareholders | 133,026 | 102,036 | 130.4% | ||
| Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: DR. DATSONS LABS STRIDES PHARMA SCIENCE TTK HEALTHCARE JUBILANT LIFE SCIENCES BIOCON
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Slips below 38,000-Mark; Yes Bank Jumps 9%(12:30 pm)
Share markets in India are presently trading deep in the red as investors were disappointed after the government refused any respite to foreign investors.
Related Views on News
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)
May 21, 2019 | Updated on May 21, 2019For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)
Feb 5, 2019 | Updated on Feb 5, 2019For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)
Jul 15, 2019While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.
7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)
Jul 18, 2019Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
More|
| |
SUN PHARMA SHARE PRICE
Jul 22, 2019 12:55 PM
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 5-YR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.